Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD8853 in Advanced Solid Tumors
NCT05397171Phase 2Terminated
- Sponsor
- AstraZeneca
- Start
- Jun 2022
- Primary completion
- Jun 2023
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of AZD8853 in non-small cell lung cancer (NSCLC), colorectal cancer (CRC), urothelial carcinoma (UC), sponsored by AstraZeneca. Started Jun 2022; status: terminated.
02
Drugs
AZD8853
03
Conditions
non-small cell lung cancer (NSCLC)colorectal cancer (CRC)urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT05397171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05397171.